Novartis, the Swiss pharmaceutical company, has halted its phase 3 study of the biologic drug ligelizumab for peanut allergy this January, but plans to launch a new study at a different dose. If approved, the study will begin in Autumn 2024.

A new review of the existing evidence, published in the British Medical Journal (the BMJ), has found that introducing allergen-containing food to infants’ diets from the age of 4 to 12 months was associated with a lower risk of multiple food allergies and eczema.

Researchers from the Aston University aim to explore potential predictors of anxiety and quality of life in parents of children with food allergies, with intentions of gaining a greater understanding surrounding the complexities of caring for children with these medical needs.

Researchers from the University of Aston are looking for parents and carers of children with a food allergy and either asthma, eczema or allergic rhinitis to talk about their experiences in a new study, aiming to improve understanding and support for caregivers.

A round-up of food immunotherapy studies published in the last month.

New research finds that measuring water loss through the skin during food challenges can predict anaphylaxis before symptoms appear, increasing patient comfort and safety.

Researches in the US have completed a trial examining the safety and efficacy of sublingual immunotherapy and found it has potential for long lasting effects and is most effective in young children.

The biopharmaceutical company DBV Technologies is due to begin two safety trials for Viaskin Peanut in two age groups, known as COMFORT Toddlers and COMFORT Children.

Researchers based at Birmingham Heartlands Hospital are inviting health professionals to take part in The FAIR Study to benefit patients from a South Asian Background with food allergies.